Literature DB >> 12224012

Evaluation of Tet-on system to avoid transgene down-regulation in ex vivo gene transfer to the CNS.

J Johansen1, C Rosenblad, K Andsberg, A Møller, C Lundberg, A Björlund, T E Johansen.   

Abstract

Ex vivo gene transfer to the CNS has so far been hampered by instability of transgene expression. To avoid the phenomenon of transgene down-regulation, we have employed strong, constitutive promoters and compared this expression system with the inducible Tet expression system incorporated in a single plasmid vector or in lentiviral vectors. Plasmid-based transgene expression directed by the constitutive, human ubiquitin promoter, UbC, was stable in transfected HiB5 cells in vitro and comparable in strength to the CMV promoter. However, after transplantation of UbC and CMV HiB5 clones to the rat striatum, silencing of the transgene occurred in most cells soon after implantation of transfected cells. The Tet-on elements were incorporated in a single plasmid vector and inducible HiB5 clones were generated. Inducible clones displayed varying basal expression activity, which could not be ascribed to an effect of cis-elements in the vector, but rather was due, at least in part, to intrinsic activity of the minimal promoter. Basal expression activity could be blocked in a majority of cells by stable expressing the transrepressor tTS. Fully induced expression levels were comparable to CMV and UbC promoters. Similar to the constitutive promoters transgene expression was down-regulated soon after grafting of inducible HiB5 clones to the rat striatum. Lentiviral vectors can direct long-term stable in vivo transgene expression. To take advantage of this quality of the lentiviral vector, the Tet-on elements were incorporated in two lentiviral transfer vectors followed by transduction of Hib5 cells. Interestingly, all HiB5 clones established by lentiviral transduction showed very similar expression patterns and tight regulatability that apparently was independent of transgene copy number and integration site. Nevertheless, transgene expression in all lentiviral HiB5 clones was down-regulated shortly after transplantation to the rat striatum. These results confirm the general phenomenon of transgene down-regulation. Moreover, the results suggest that the considerable advantages offered by lentiviral vectors for direct gene delivery cannot necessarily be transferred directly to ex vivo gene delivery. This emphasizes the need for alternative vector strategies for ex vivo gene transfer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12224012     DOI: 10.1038/sj.gt.3301778

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  17 in total

Review 1.  Regulatable gene expression systems for gene therapy applications: progress and future challenges.

Authors:  S Goverdhana; M Puntel; W Xiong; J M Zirger; C Barcia; J F Curtin; E B Soffer; S Mondkar; G D King; J Hu; S A Sciascia; M Candolfi; D S Greengold; P R Lowenstein; M G Castro
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

Review 2.  Regulatable gene expression systems for gene therapy.

Authors:  Nuria Vilaboa; Richard Voellmy
Journal:  Curr Gene Ther       Date:  2006-08       Impact factor: 4.391

3.  Design of a Lentiviral Vector for the Inducible Expression of MYC: A New Strategy for Construction Approach.

Authors:  Onur Tokgun; Francesco Paolo Fiorentino; Pervin Elvan Tokgun; Jun Yokota; Hakan Akca
Journal:  Mol Biotechnol       Date:  2017-06       Impact factor: 2.695

Review 4.  Lentiviral vectors in gene therapy: their current status and future potential.

Authors:  David Escors; Karine Breckpot
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-02-09       Impact factor: 4.291

5.  Gene delivery to the spinal cord: comparison between lentiviral, adenoviral, and retroviral vector delivery systems.

Authors:  Ahmed A Abdellatif; Jennifer L Pelt; Richard L Benton; Russell M Howard; Pantelis Tsoulfas; Peipei Ping; Xiao-Ming Xu; Scott R Whittemore
Journal:  J Neurosci Res       Date:  2006-08-15       Impact factor: 4.164

6.  A new versatile and compact lentiviral vector.

Authors:  Jens Leander Johansen; Lone Dagø; Jens Tornøe; Carl Rosenblad; Philip Kusk
Journal:  Mol Biotechnol       Date:  2005-01       Impact factor: 2.695

7.  Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses.

Authors:  Weidong Xiong; Shyam Goverdhana; Sandra A Sciascia; Marianela Candolfi; Jeffrey M Zirger; Carlos Barcia; James F Curtin; Gwendalyn D King; Gabriela Jaita; Chunyan Liu; Kurt Kroeger; Hasmik Agadjanian; Lali Medina-Kauwe; Donna Palmer; Philip Ng; Pedro R Lowenstein; Maria G Castro
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

8.  Design and in vivo characterization of self-inactivating human and non-human lentiviral expression vectors engineered for streptogramin-adjustable transgene expression.

Authors:  Barbara Mitta; Cornelia C Weber; Markus Rimann; Martin Fussenegger
Journal:  Nucleic Acids Res       Date:  2004-07-16       Impact factor: 16.971

9.  The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.

Authors:  Hong Yu; Ronan McDaid; John Lee; Patricia Possik; Ling Li; Suresh M Kumar; David E Elder; Patricia Van Belle; Phyllis Gimotty; Matt Guerra; Rachel Hammond; Katharine L Nathanson; Maria Dalla Palma; Meenhard Herlyn; Xiaowei Xu
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

10.  Comparison of optical bioluminescence reporter gene and superparamagnetic iron oxide MR contrast agent as cell markers for noninvasive imaging of cardiac cell transplantation.

Authors:  Ian Y Chen; Joan M Greve; Olivier Gheysens; Jürgen K Willmann; Martin Rodriguez-Porcel; Pauline Chu; Ahmad Y Sheikh; Anthony Z Faranesh; Ramasamy Paulmurugan; Phillip C Yang; Joseph C Wu; Sanjiv S Gambhir
Journal:  Mol Imaging Biol       Date:  2008-11-25       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.